Role of high-volume plasmapheresis in the management of paediatric acute liver failure.
HVP
PALF
extracorporeal liver support
hepatic regeneration
plasma exchange
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
revised:
19
02
2024
received:
28
10
2023
accepted:
21
03
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Paediatric acute liver failure (PALF) is a life-threatening disease. Management aims to support hepatic regeneration or to bridge to liver transplantation. High-volume plasmapheresis (HVP) removes protein-bound substances, alleviates inflammation, and improves survival in adult acute liver failure. However, experience with HVP in PALF is limited. Aim of this study is to report on feasibility, safety, efficacy and outcomes of HVP in PALF. Retrospective observational study in children with PALF. HVP was performed upon identification of negative prognostic indicators, in toxic aetiology or multiorgan failure (MOF). Exchanged volume with fresh-frozen plasma corresponded to 1.5-2.0 times the patient's estimated plasma volume. One daily cycle was performed until the patient met criteria for discontinuation, that is, liver regeneration, liver transplantation, or death. Twenty-two children with PALF (body weight 2.5-106 kg) received 1-7 HVP cycles. No bleeding or procedure-related mortality occurred. Alkalosis, hypothermia and reduction in platelets were observed. Haemolysis led to HVP termination in one infant. Seven children (32%) survived with their native livers, 13 patients (59%) underwent liver transplantation. Two infants died due to MOF. Overall survival was 86%. International normalization ratio (INR), alanine aminotransaminases (ALT), bilirubin and inotropic support were reduced significantly (p < 0.05) after the first HVP-cycle (median): INR 2.85 versus 1.5; ALT 1280 versus 434 U/L; bilirubin 12.7 versus 6.7 mg/dL; norepinephrine dosage 0.083 versus 0.009 µg/kg/min. Median soluble-interleukin-2-receptor dropped significantly following HVP (n = 7): 2407 versus 950 U/mL (p < 0.02). HVP in PALF is feasible, safe, improves markers of liver failure and inflammation and is associated with lowering inotropic support. Prospective and controlled studies are required to confirm efficacy of HVP in PALF.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : None
Informations de copyright
© 2024 The Authors. Journal of Pediatric Gastroenterology and Nutrition published by Wiley Periodicals LLC on behalf of European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.Gastroenterology, Hepatology, and Nutrition.
Références
Squires RH, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006;148:652‐658.
Narkewicz MR, Horslen S, Hardison RM, et al. A learning collaborative approach increases specificity of diagnosis of acute liver failure in pediatric patients. Clin Gastroenterol Hepatol. 2018;16:1801‐1810.e3.
Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525‐2534.
Grazioli S, Deep A. High‐volume plasmapheresis in children with acute liver failure: another brick in the wall in the current management? J Pediatr Gastroenterol Nutr. 2021;72:786‐787.
Squires JE, Alonso EM, Ibrahim SH, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the diagnosis and management of pediatric acute liver failure. J Pediatr Gastroenterol Nutr. 2022;74:138‐158.
Deep A, Nagakawa S, Tissieres P. Non‐transplant options in paediatric acute liver failure‐what is new? Intens Care Med. 2022;48:114‐117.
Singer AL, Olthoff KM, Kim H, Rand E, Zamir G, Shaked A. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg. 2001;234:418‐424.
Stahl K, Hadem J, Schneider A, et al. Therapeutic plasma exchange in acute liver failure. J Clin Apheresis. 2019;34:589‐597.
Deep A, Stewart CE, Dhawan A, Douiri A. Effect of continuous renal replacement therapy on outcome in pediatric acute liver failure. Crit Care Med. 2016;44:1910‐1919.
Davenport A. Continuous renal replacement therapy for liver disease. Hemodialysis International. 2003;7:348‐352.
Larsen FS, Schmidt LE, Bernsmeier C, et al. High‐volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64:69‐78.
Ide K, Muguruma T, Shinohara M, et al. Continuous Veno‐Venous hemodiafiltration and plasma exchange in infantile acute liver failure. Pediatr Crit Care Med. 2015;16:e268‐e274.
Rodriguez K, Srivaths PR, Tal L, et al. Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure. PLoS One. 2017;12:e0182134.
Jørgensen MH, Rasmussen A, Christensen VB, et al. Safety of high‐volume plasmapheresis in children with acute liver failure. J Pediatr Gastroenterol Nutr. 2021;72:815‐819.
Pawaria A, Sood V, Lal BB, Khanna R, Bajpai M, Alam S. Ninety days transplant free survival with high volume plasma exchange in Wilson disease presenting as acute liver failure. J Clin Apheresis. 2021;36:109‐117.
Schaefer B, Schaefer F, Engelmann G, et al. Comparison of Molecular Adsorbents Recirculating System (MARS) dialysis with combined plasma exchange and haemodialysis in children with acute liver failure. Nephrol Dial Transplant. 2011;26:3633‐3639.
Tufan Pekkucuksen N, Sigler KE, Akcan Arikan A, Srivaths P. Tandem plasmapheresis and continuous kidney replacement treatment in pediatric patients. Pediatr Nephrol. 2021;36:1273‐1278.
Gun E, Durak A, Botan E, et al. Extracorporeal therapies in children with acute liver failure: a single‐center experience. Turk J Gastroenterol. 2023;34:73‐79.
Chien M‐M, Chang M‐H, Chang K‐C, et al. Prognostic parameters of pediatric acute liver failure and the role of plasma exchange. Pediatr Neonatol. 2019;60:389‐395.
Akcan Arikan A, Srivaths P, Himes RW, et al. Hybrid extracorporeal therapies as a bridge to pediatric liver transplantation. Pediatr Crit Care Med. 2018;19:e342‐e349.
Jain V, Dhawan A. Extracorporeal liver support systems in paediatric liver failure. J Pediatr Gastroenterol Nutr. 2017;64:855‐863.
Atay G, Demirkol D. Therapeutic plasma exchange application in children requires individual decision. J Pediatr Intens Care. 2021;10:106‐109.
Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli‐Vergani G. Wilson's disease in children: 37‐year experience and revised King's score for liver transplantation. Liver Transpl. 2005;11:441‐448.
Lu BR, Zhang S, Narkewicz MR, Belle SH, Squires RH, Sokol RJ. Evaluation of the liver injury unit scoring system to predict survival in a multinational study of pediatric acute liver failure. J Pediatr. 2013;162:1010‐1016.e4.
Straney L, Clements A, Parslow RC, et al. Paediatric index of mortality 3: an updated model for predicting mortality in pediatric intensive care*. Pediatr Crit Care Med. 2013;14:673‐681.
Ng VL, Li R, Loomes KM, et al. Outcomes of children with and without hepatic encephalopathy from the pediatric acute liver failure study group. J Pediatr Gastroenterol Nutr. 2016;63:357‐364.
Bucuvalas J, Filipovich L, Yazigi N, et al. Immunophenotype predicts outcome in pediatric acute liver failure. J Pediatr Gastroenterol Nutr. 2013;56:311‐315.
Chapin CA, Horslen SP, Squires JE, et al. Corticosteroid therapy for indeterminate pediatric acute liver failure and aplastic anemia with acute hepatitis. J Pediatr. 2019;208:23‐29.
Rajanayagam J, Coman D, Cartwright D, Lewindon PJ. Pediatric acute liver failure: etiology, outcomes, and the role of serial pediatric end‐stage liver disease scores. Pediatr Tranplant. 2013;17:362‐368.